Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity

Document Type : Research article


Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University (ACU), Cairo, Egypt.


Mutational inactivation of p53 is a key player in the development of human cancer. Thus, retrieving the tumor suppressor activity of p53 gene is considered a novel strategy in cancer therapy. Current study aimed to investigate the anti-cancer potentials of botulinum toxin type-A (BTX-A) and captopril as a trial to shed light on effective anti-cancer therapy with lower side effects. Cytotoxic effect of captopril and BTX-A was determined using MTT assay against colon (HCT116) and prostate cancer (DU145) cells compared to their effect on normal vero cells. Anti-proliferation assay and anti-metastatic effect were carried out using trypan blue exclusion method and wound scratch migration test, respectively. The ability of test drugs to induce apoptosis in cancer cells was examined using real time PCR. Recorded data revealed that captopril exhibited a statistically significant cytotoxicity (P < 0.05) to cancer cells (IC50 values of 1.5 and 1.2 mg/mL) with much lower toxicity to normal cells. At the same time, IC50 values post BTX-A treatment were 7.2 and 6.4 U/mL for HCT116 and DU145 cells, respectively without any toxicity to vero cells. Both drugs showed inhibitory potentials on cellular proliferation and the ability of cancer cells to migrate in scratched monolayers was obviously inhibited along with increasing their concentrations. P53 expression levels in captopril and BTX-A treated DU145 cells were elevated by 4 and 2.5 folds, respectively, while lower level of apoptosis induction in HCT116 cells was observed. Accordingly, BTX-A and captopril could present potential anti-cancer candidates through triggering cancer cells towards self-destruction.


Main Subjects

inhibition of angiogenesis by artesunate and captopril
in-vitro and in-vivo. Evid. Based Complement. Altern.
Med. (2013) 8: 2013.
Ashcroft M and Vousden KH. Regulation of p53
stability. Oncogene (1999) 18: 7637-43.
Almazov VP, Kochetkov DV and Chumakov PM. Use
of p53 for therapy of human cancer. Mol. Biol. (2007)
41: 863-77.
Heinen TE and da Veiga AB. Arthropod venoms and
cancer. Toxicon (2011) 57: 497-511.
Ansiaux R and Gallez B. Use of botulinum toxins in
cancer therapy. Expert Opin. Invest. Drugs (2007) 16:
Nigam PK and Nigam A. Botulinum toxin. Indian J.
Dermatol. (2010) 55: 8.
Cushman DW and Ondetti MA. History of the design
of captopril and related inhibitors of angiotensin
converting enzyme. Hypertension (1991) 17: 589-92.
Prisant LM. Management of hypertension in patients
with cardiac disease: use of renin-angiotensin blocking
agents. Am. J. Med. (2008) 121: S8-15.
Rosenthal T and Gavras I. Angiotensin inhibition and
malignancies: a review. J. Hum. Hypertens. (2009)
23: 623-35.
Bandala C, Perez-Santos JL, Lara-Padilla E, Delgado
L and Anaya-Ruiz M. Effect of botulinum toxin A on
proliferation and apoptosis in the T47D breast cancer
cell line. Asian Pac. J. Cancer Prev. (2013) 14: 891-4.
Zhao Y, Turlington M, LaPar DJ, Jones DR, Harris
DA, Kron IL, Pu L and Lau CL. Characterization of
novel synthesized small molecular compounds against
non-small cell lung cancer. Ann. Thorac. Surg. (2011)
92: 1031-7.
García-Vilas JA, Quesada AR and Medina MA.
Damnacanthal, a noni anthraquinone, inhibits c-Met
and is a potent antitumor compound against Hep
G2 human hepatocellular carcinoma cells. Sci. Rep.
(2015) 5: 8021.
Tang XP, Tang GD, Fang CY, Liang ZH and Zhang LY.
Effects of ginsenoside Rh2 on growth and migration of
pancreatic cancer cells. World J. Gastroenterol. (2013)
19: 1582-92.
Steuerwald N, Cohen J, Herrera RJ and Brenner
CA. Analysis of gene expression in single oocytes
and embryos by real-time rapid cycle fluorescence
monitored RT–PCR. Mol. Hum. Reprod. (1999) 5:
Wang Z and Sun Y. Targeting p53 for novel anticancer
therapy. Transl. Oncol. (2010) 3: 1-12.
Gudkov AV and Komarova EA. Dangerous habits of a
security guard: the two faces of p53 as a drug target.
Hum. Mol. Gen. (2007) 16: R67-72.
Hamedeyazdan S, Fathiazad F, Sharifi S and
Nazemiyeh H. Antiproliferative activity of Marrubium
persicum extract in the MCF-7 human breast cancer
cell line. Asian Pac. J. Cancer Prev. (2012) 13: 5843-8.
Green DR and Kroemer G. Cytoplasmic functions of
the tumor suppressor p53. Nature (2009) 458: 1127-
Yu X, Narayanan S, Vazquez A and Carpizo DR. Small
Liu CC, Yang H, Zhang LL, Zhang Q, Chen B and
Wang Y. Biotoxins for cancer therapy. Asian Pac. J.
Cancer Prev. (2013) 15: 4753-8.
Krusche B, Arend J and Efferth T. Synergistic
Captopril and Botulinum Toxin Anticancer Potentials
molecule compounds targeting the p53 pathway: are
we finally making progress? Apoptosis (2014) 19:
Parrales A and Iwakuma T. Targeting oncogenic mutant
p53 for cancer therapy. Front. Oncol. (2015) 5: 288.
Roth JA. Adenovirus p53 gene therapy. Expert Opin.
Biol. Ther. (2006) 6: 55-61.
Selivanova GA, Wiman KG. Reactivation of mutant
p53: molecular mechanisms and therapeutic potential.
Oncogene (2007) 26: 2243-54.
Wienken M, Dickmanns A, Nemajerova A, Kramer D,
Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang
Y, Lozano G and Johnsen SA. MDM2 associates with
polycomb repressor complex 2 and enhances stemnesspromoting chromatin modifications independent of
p53. Mol. Cell (2016) 61: 68-83.
Shangary S, Qin D, McEachern D, Liu M, Miller
RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G,
Chen J and Bernard D. Temporal activation of p53
by a specific MDM2 inhibitor is selectively toxic to
tumors and leads to complete tumor growth inhibition.
Proceedings of the National Academy of Sciences
(2008) 105: 3933-8.
Sun SH, Zheng M, Ding K, Wang S and Sun Y. A small
molecule that disrupts Mdm2-p53 binding activates
p53, induces apoptosis, and sensitizes lung cancer
cells to chemotherapy. Cancer Biol. Ther. (2008) 7:
Khan MH, Fazal S, Bano R and Rashid H. A miracle if
restored, p53. Afr. J. Biotechnol. (2013) 12: 3745-51.
Ronquist G, Rodríguez LA, Ruigómez A, Johansson S,
Wallander MA, Frithz G and Svärdsudd K. Association
between captopril, other antihypertensive drugs and
risk of prostate cancer. Prostate (2004) 58: 50-6.
Duchin KL, McKinstry DN, Cohen AI and Migdalof
BH. Pharmacokinetics of captopril in healthy subjects
and in patients with cardiovascular diseases. Clin.
Pharmacokinet. (1988) 14: 241-59.
Shukla HD and Sharma SK. Clostridium botulinum:
a bug with beauty and weapon. Crit. Rev. Microbiol.
(2005) 31: 11-8.
Muthane UB and Panikar DN. Botulinum toxins:
pharmacology and its current therapeutic evidence for
use. Neurol. India (2003) 51: 455-60.
Jost WH, Blümel J and Grafe S. Botulinum neurotoxin
type A free of complexing proteins (XEOMIN®) in
focal dystonia. Drugs (2007) 67: 669-83.
Zhu H, Mao Q, Lin Y, Yang K and Xie L. RNA
interference targeting mutant p53 inhibits growth and
induces apoptosis in DU145 human prostate cancer
cells. Med. Oncol. (2011) 28: 381-7.
Kochi T, Shimizu M, Ohno T, Baba A, Sumi T, Kubota
M, Shirakami Y, Tsurumi H and Tanaka T, Moriwaki
H. Preventive effects of the angiotensin converting
enzyme inhibitor, captopril, on the development of
azoxymethane induced colonic preneoplastic lesions
in diabetic and hypertensive rats. Oncol. Lett. (2014)
8: 223-9.
Karpiński TM and Szkaradkiewicz AK. Anticancer
peptides from bacteria. Bangladesh J. Pharmacol.
(2013) 8: 343-8.
Zhang Y, Schulte W, Pink D, Phipps K, Zijlstra A,
Lewis JD and Waisman DM. Sensitivity of cancer
cells to truncated diphtheria toxin. PLoS One (2010)
5: e10498.
Patyar S, Joshi R, Byrav DP, Prakash A, Medhi B
and Das BK. Bacteria in cancer therapy: a novel
experimental strategy. J. Biomed. Sci. (2010) 17: 1.
Proietti S, Nardicchi V, Porena M and Giannantoni
A. Botulinum toxin type-A toxin activity on prostate
cancer cell lines. Urologia (2011) 79: 135-41.
Jung NH, Chang JS, Nam ST, Kim SK, Seok H
and Park YJ. Cells transformed by PLC-gamma 1
overexpression are highly sensitive to clostridium
difficile toxin A-induced apoptosis and mitotic
inhibition. J. Microbiol. Biotechnol. (2012) 22: 50-7.
Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu
C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA and
Corcos J. Botulinum toxin type A inhibits the growth
of LNCaP human prostate cancer cells in-vitro and
in-vivo. Prostate (2009) 69: 1143-50.
Small Jr W, Molteni A, Kim YT, Taylor JM and Ward
WF. Mechanism of captopril toxicity to a human
mammary ductal carcinoma cell line in the presence
of copper. Breast Cancer Res. Treat. (1999) 55: 223-9.
Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N,
Petrovic T and Juranic Z. Inhibition of proliferation
on some neoplastic cell lines-act of carvedilol and
captopril. J. Exp. Clin. Cancer Res. (2005) 24: 387-95.
O’Donnell PH and Dolan ME. Cancer pharmacoethnicity:
ethnic differences in susceptibility to the effects of
chemotherapy. Clin. Cancer Res. (2009) 15: 4806-14.
Wen SW, Ager EI, Neo J and Christophi C. The
renin angiotensin system regulates Kupffer cells in
colorectal liver metastases. Cancer Biol. Ther. (2013)
14: 720-7.
Attoub S, Gaben AM, Al‐Salam S, Al Sultan MA, John
A, Nicholls MG, Mester J and Petroianu G. Captopril
as a potential inhibitor of lung tumor growth and
metastasis. Ann. N. Y. Acad. Sci. (2008) 1138: 65-72.
Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao
W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec
E, Halayko AJ and Los M. Apoptosis and cancer:
mutations within caspase genes. J. Med. Genet. (2009)
46: 497-510.
Pistritto G, Trisciuoglio D, Ceci C, Garufi A and
D′Orazi G. Apoptosis as anticancer mechanism:
function and dysfunction of its modulators and targeted
therapeutic strategies. Aging (2016) 8: 603-19.
Ozaki T and Nakagawara A. Role of p53 in cell death
and human cancers. Cancers (2011) 3: 994-1013.
Kozera B and Rapacz M. Reference genes in real-time
PCR. J. Appl. Genet. (2013) 54: 391-406.
Hsu YC, Wang HJ and Chuang YC. Intraprostatic
botulinum neurotoxin type A injection for benign
prostatic hyperplasia-A spotlight in reality. Toxins
(2016) 8: 126.
Mouhayar E and Salahudeen A. Hypertension in
cancer patients. Tex. Heart Inst. J. (2011) 38: 263-5.